Uveal Melanoma - Pipeline Review, H1 2015

Published: Mar, 2015 | Pages: 86 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Uveal Melanoma - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Uveal Melanoma - Pipeline Review, H1 2015’, provides an overview of the Uveal Melanoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Uveal Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uveal Melanoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Uveal Melanoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Uveal Melanoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Uveal Melanoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Uveal Melanoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Uveal Melanoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Uveal Melanoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Uveal Melanoma Overview 7
Therapeutics Development 8
Pipeline Products for Uveal Melanoma - Overview 8
Pipeline Products for Uveal Melanoma - Comparative Analysis 9
Uveal Melanoma - Therapeutics under Development by Companies 10
Uveal Melanoma - Therapeutics under Investigation by Universities/Institutes 11
Uveal Melanoma - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Uveal Melanoma - Products under Development by Companies 15
Uveal Melanoma - Products under Investigation by Universities/Institutes 16
Uveal Melanoma - Companies Involved in Therapeutics Development 17
Array BioPharma Inc. 17
AstraZeneca PLC 18
Celldex Therapeutics, Inc. 19
Eli Lilly and Company 20
GlaxoSmithKline plc 21
Novartis AG 22
Pfizer Inc. 23
Spectrum Pharmaceuticals, Inc. 24
Uveal Melanoma - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Combination Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
binimetinib - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
crizotinib - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Dendritic Cell Therapy to Target Melan-A, MAGE-3 and Survivin for Melanoma and Uveal Melanoma - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
emibetuzumab - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
glembatumumab vedotin - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
merestinib - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
nutlin-3 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
pasireotide LAR - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
selumetinib sulfate - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
sotrastaurin acetate - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
sunitinib malate - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
trametinib dimethyl sulfoxide + uprosertib - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
vincristine sulfate - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Uveal Melanoma - Recent Pipeline Updates 65
Uveal Melanoma - Dormant Projects 83
Uveal Melanoma - Product Development Milestones 84
Featured News & Press Releases 84
Jun 01, 2013: AstraZeneca's New Therapy Selumetinib Improves Progression-Free Survival And Shrink Tumors In Metastatic Uveal Melanoma, Researchers Report 84
Appendix 85
Methodology 85
Coverage 85
Secondary Research 85
Primary Research 85
Expert Panel Validation 85
Contact Us 85
Disclaimer 86

List of Tables

Number of Products under Development for Uveal Melanoma, H1 2015 8
Number of Products under Development for Uveal Melanoma - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Late Stage Development, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Products under Investigation by Universities/Institutes, H1 2015 16
Uveal Melanoma - Pipeline by Array BioPharma Inc., H1 2015 17
Uveal Melanoma - Pipeline by AstraZeneca PLC, H1 2015 18
Uveal Melanoma - Pipeline by Celldex Therapeutics, Inc., H1 2015 19
Uveal Melanoma - Pipeline by Eli Lilly and Company, H1 2015 20
Uveal Melanoma - Pipeline by GlaxoSmithKline plc, H1 2015 21
Uveal Melanoma - Pipeline by Novartis AG, H1 2015 22
Uveal Melanoma - Pipeline by Pfizer Inc., H1 2015 23
Uveal Melanoma - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2015 24
Assessment by Monotherapy Products, H1 2015 25
Assessment by Combination Products, H1 2015 26
Number of Products by Stage and Target, H1 2015 28
Number of Products by Stage and Mechanism of Action, H1 2015 30
Number of Products by Stage and Route of Administration, H1 2015 32
Number of Products by Stage and Molecule Type, H1 2015 34
Uveal Melanoma Therapeutics - Recent Pipeline Updates, H1 2015 65
Uveal Melanoma - Dormant Projects, H1 2015 83